



## Functional Nanohybrids for Drug Delivery

Guest Editors:

**Dr. Shang-Hsiu Hu**

Department of Biomedical  
Engineering and Environmental  
Sciences, National Tsing Hua  
University, Hsinchu 300044,  
Taiwan

**Dr. Chien-Wen Chang**

Biomedical Engineering and  
Environmental Sciences,  
National Tsing Hua University,  
Hsinchu 30013, Taiwan

Deadline for manuscript  
submissions:

**closed (30 January 2019)**

### Message from the Guest Editors

Dear Colleagues,

Nanomaterial-based drug delivery systems have been seen as a publicly-known strategy to improve therapeutic efficacy in cancer therapies. However, dense extracellular matrix and interstitial fluid pressure in the tumor suppress deep delivery and lead to inhomogeneous treatments. Not only able to accumulate at highly permeable peripheral blood vessels via enhanced permeability and retention effects, nanohybrids should also be concerned with different functions to enhance drug delivery. Stimuli-response and functions of nanohybrids are two impressive manipulations. In addition, targeting moiety for specific diseases also shelters the mononuclear phagocyte system and promotes drug delivery. Therefore, blood circulation obstacles, tumor accumulation, and penetrated delivery should be comprehensively considered, thus multifunctional nanohybrids will be the ideal platforms for enhanced drug delivery. The development of new nanohybrids is an important step of drug delivery systems. This Special Issue aims of highlighting current progress in multifunctional nanohybrids for enhanced drug delivery.

Prof. Shang-Hsiu Hu  
Prof. Chien-Wen Chang





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma